Rallybio Corp.
Chart
Good to know: Investing in stocks tends to provide long-term positive returns, but it also involves risks. You can lose some or all of your investment. Past performance of this stock is not a reliable indicator of future results. Data from external providers has not been altered by Saxo. See full data disclaimer
About Rallybio Corp.
Rallybio Corp is a clinical-stage biotechnology company engaged in the development of therapeutic candidates for severe and rare diseases. It focuses on the treatment of conditions related to complement dysregulation and hematologic disorders. The company's flagship program, RLYB116, is a C5 inhibitor being evaluated for potential use in diseases associated with complement dysregulation, including immune platelet transfusion refractoriness and refractory antiphospholipid syndrome. Its pipeline also includes RLYB332, a preclinical long-acting matriptase-2 antibody candidate under investigation for the treatment of iron overload disorders.
/ 
Others were interested in
See all stocksFrequently asked questions
To buy Rallybio Corp. stock, open a Saxo account and fund it. With SaxoInvestor or SaxoTrader, you can easily search for Rallybio Corp. by name or ticker, choose the number of shares, and place your order.
The ticker symbol for Rallybio Corp. is RLYB:xnas. You can use this code to quickly find the stock in Saxo’s platforms and track its price and performance.
Rallybio Corp. has its primary listing on NASDAQ. You can trade Rallybio Corp. with a Saxo account, alongside thousands of other stocks worldwide.
Yes, Rallybio Corp. is available to trade on SaxoInvestor and SaxoTrader. You can buy shares directly and include Rallybio Corp. as part of a broader investment portfolio.
Learn more about investing and trading in Saxo's education hub. Explore portfolio strategies, types of stocks, diversification, and valuation measures—so you can make more informed decisions when considering shares like Rallybio Corp. or others.